DCUN1D5 is a novel potential biomarker for predicting the prognosis of bladder cancer

Bladder cancer is a malignant tumor ranks among the most common urogenital malignancies. Treatment efficacy specifically in MIBC remains suboptimal due to profound tumor heterogeneity. Gene and protein biomarkers provide the opportunity for precise diagnosis and treatment. In this study, by using bioinformatic portals, we identified DCUN1D5 as an upregulated gene that may influence pan-cancer prognosis. Its expression showed significant differences across histological grades and tumor subtypes in BLCA. We found that co-expression genes of DCUN1D5 were enriched in translation initiation factor activity and methyltransferase activity, suggesting potential regulatory mechanisms of DCUN1D5. Furthermore, we validated the prognostic role of DCUN1D5 in BLCA through immunohistochemical analysis of 56 tissue microarray samples. The relationship between DCUN1D5 expression and clinicopathological parameters of BLCA was analyzed by Chi-square test, and result was consistent with bioinformatic analysis. In conclusion, we identified DCUN1D5 as a novel potential Biomarker for predicting the prognosis of BLCA.